作者
Paul M Ridker, Samuel Z Goldhaber, Ellie Danielson, Yves Rosenberg, Charles S Eby, Steven R Deitcher, Mary Cushman, Stephan Moll, Craig M Kessler, C Gregory Elliott, Rolf Paulson, Turnly Wong, Kenneth A Bauer, Bruce A Schwartz, Joseph P Miletich, Henri Bounameaux, Robert J Glynn
发表日期
2003/4/10
期刊
New England Journal of Medicine
卷号
348
期号
15
页码范围
1425-1434
出版商
Massachusetts Medical Society
简介
Background
Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0. However, for long-term management, no therapeutic agent has shown an acceptable benefit-to-risk ratio.
Methods
Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months were randomly assigned to placebo or low-intensity warfarin (target INR, 1.5 to 2.0). Participants were followed for recurrent venous thromboembolism, major hemorrhage, and death.
Results
The trial was terminated early after 508 patients had undergone randomization and had been followed for up to 4.3 years (mean, 2.1). Of 253 patients assigned to placebo, 37 had recurrent venous thromboembolism (7.2 per 100 person-years), as compared with 14 of 255 …
引用总数
学术搜索中的文章
PM Ridker, SZ Goldhaber, E Danielson, Y Rosenberg… - New England Journal of Medicine, 2003